Zhejiang Medicine Co., Ltd. (SHA:600216)
China flag China · Delayed Price · Currency is CNY
11.14
-0.14 (-1.24%)
Nov 6, 2026, 3:00 PM CST

Zhejiang Medicine Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
8,3858,8349,3367,7628,0739,088
Other Revenue
46.2346.2338.7632.1143.2341.3
8,4318,8819,3757,7948,1169,129
Revenue Growth
-5.88%-5.28%20.29%-3.96%-11.10%24.60%
Cost of Revenue
5,8445,9845,5915,3925,4385,530
Gross Profit
2,5872,8963,7852,4022,6783,599
Selling, General & Admin
1,4141,4091,6781,4811,3121,546
Research & Development
491.2579.88749.35860.07809.28806.86
Other Operating Expenses
63.4451.3753.8552.369.8675.17
Operating Expenses
1,9722,0372,4942,3942,1882,439
Operating Income
614.83859.521,2917.98489.741,160
Interest Expense
-6.35-24.82-26.37-28.34-33.11-39.54
Interest & Investment Income
64.2932.7222.5116.5113.1857.42
Currency Exchange Gain (Loss)
74.9774.9717.8236.5966.6-64.31
Other Non Operating Income (Expenses)
-198.42-5.23.921.09-36.73-2.69
EBT Excluding Unusual Items
549.33937.21,30853.83499.671,111
Impairment of Goodwill
---18.68-9.23-8.12-
Gain (Loss) on Sale of Investments
-25.374.64-29.6-28.59-56.5151.73
Gain (Loss) on Sale of Assets
-0.96-6.56-5.21323.57-1.37-7.95
Asset Writedown
-1.82-25.62-69.41---46.19
Other Unusual Items
50.2642.0726.7723.6957.7144.76
Pretax Income
571.44951.731,212363.28491.391,154
Income Tax Expense
127.37191.49192.0386.48128.77268.97
Earnings From Continuing Operations
444.06760.241,020276.79362.61884.56
Minority Interest in Earnings
188.97113.14140.26152.85176.96160.76
Net Income
633.03873.381,161429.64539.571,045
Net Income to Common
633.03873.381,161429.64539.571,045
Net Income Growth
-49.11%-24.74%170.11%-20.37%-48.38%45.71%
Shares Outstanding (Basic)
955955959955964959
Shares Outstanding (Diluted)
955955959955964959
Shares Change
-0.23%-0.42%0.46%-0.91%0.47%0.26%
EPS (Basic)
0.660.911.210.450.561.09
EPS (Diluted)
0.660.911.210.450.561.09
EPS Growth
-49.40%-24.79%168.89%-19.64%-48.62%45.33%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
459.581,439534.15-162.56-455.39197.05
Free Cash Flow Per Share
0.481.510.56-0.17-0.470.20
Dividend Per Share
0.2800.2800.3700.1500.1700.330
Dividend Growth
-24.32%-24.32%146.67%-11.77%-48.48%43.48%
Gross Margin
30.69%32.61%40.37%30.82%33.00%39.43%
Operating Margin
7.29%9.68%13.77%0.10%6.03%12.71%
Profit Margin
7.51%9.84%12.38%5.51%6.65%11.45%
Free Cash Flow Margin
5.45%16.21%5.70%-2.09%-5.61%2.16%
EBITDA
1,3161,5692,013732.171,1711,747
EBITDA Margin
15.60%17.67%21.47%9.39%14.42%19.14%
D&A For EBITDA
700.78709.85721.94724.19680.81586.79
EBIT
614.83859.521,2917.98489.741,160
EBIT Margin
7.29%9.68%13.77%0.10%6.03%12.71%
Effective Tax Rate
22.29%20.12%15.84%23.81%26.21%23.32%
Revenue as Reported
2,1858,8819,3757,7948,1169,129
Advertising Expenses
-9.4518.4621.2519.5921.3